0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Academic Alert |

New Approach to Myasthenia Gravis

Marsha F. Goldsmith
JAMA. 2001;285(17):2185. doi:10.1001/jama.285.17.2185-JAA10000-2-1.
Text Size: A A A
Published online

Extract

A unique approach to the treatment of myasthenia gravis is almost ready for trial in an animal model of the disease at the University of California, Davis, School of Medicine. David P. Richman, MD, chair of the Department of Neurology, and colleagues have been working for 25 years to develop a safer and more effective treatment than the combination of existing therapies that has improved the lives of many patients at the UC Davis Medical Center's Myasthenia Gravis Clinic.

Immunosuppressive agents loom large in current treatment for the autoimmune form of the disease, in which the immune system sends antibodies to attack acetylcholine receptors on the muscle surface at the neuromuscular junction. With receptors dead or blocked, various voluntary muscles cannot receive input from nerves across the gap and patients may become unable, for example, to focus their eyes or breathe deeply. (In the congenital form of the disease, genetic error obliterates the nerve-muscle interface.) However, because immunosuppressive drugs can eventually cause problems like the development of diabetes or cataracts, new agents are being sought.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Cortactin Autoantibodies in Myasthenia Gravis. Autoimmun Rev Published online Sep 2, 2014.;
Jobs
JAMAevidence.com

The Rational Clinical Examination
Make the Diagnosis: Myasthenia Gravis

The Rational Clinical Examination
Original Article: Does This Patient Have Myasthenia Gravis?

brightcove.createExperiences();